Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04849364
Title Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)
Acronym PERSEVERE
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Bryan Schneider, MD
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
University of Alabama at Birmingham Birmingham Alabama 35294 United States Details
Georgetown University Washington District of Columbia 20057 United States Details
Memorial Healthcare System Hollywood Florida 33028 United States Details
Miami Cancer Institute at Baptist Health, Inc. Miami Florida 33176 United States Details
University of Chicago Medical Center Chicago Illinois 60637 United States Details
Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis Indiana 46202 United States Details
Summit Health Berkeley Heights New Jersey 07922 United States Details
Novant Health Cancer Institute Winston-Salem North Carolina 27103 United States Details
Mays Cancer Center at UT Health San Antonio San Antonio Texas 78229 United States Details
University of Wisconsin Madison Wisconsin 53705 United States Details
Froedtert and The Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
Advocate Aurora Research Institute (Illinois) Wauwatosa Wisconsin 53226 United States Details
Aurora Health Care Wauwatosa Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field